Pfizer, a widely known biopharmaceutical company based in America, has been at the forefront of the race to develop a COVID-19 vaccine ever since the quarantine began. Up until recently, the company has only performed their vaccine trials on individuals over the age of 16, with the majority of trials being performed on an older crowd. However, it’s become clear after the pandemic’s inception that children under the age of 16 are also susceptible to the virus, and so, Pfizer has just announced that it has gotten FDA approval to accept children as young as 12 years of age to enroll in their trials. Pfizer’s goal for this venture is to obtain more information about the efficiency of their vaccine in younger individuals with diverse backgrounds. This is a move that has been supported by the American Academy of Pediatricians (AAP), as detailed in its formal letter to the Secretary of Health and Human Services and the Commissioner of the US Food and Drug Administration. As the AAP president, Sara Goza, states, “We urge the inclusion of children in vaccine trials as we move forward in the development of a SARS-CoV-2 vaccine.” Other pharmaceutical companies that are also working on COVID-19 vaccines, such as Janssen, Moderna, and AstraZeneca, have been focusing on adults for their phase 3 vaccine trials—however, this announcement from Pfizer might just be the push that also causes these other companies to extend beyond strictly adult data collection.